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ABSTRACT 29 
Introduction: Oxidative stress may play an important role in the pathophysiology of cystic 30 
fibrosis (CF). This review aimed to quantify CF-related redox imbalances.  31 
Methods: Systematic searches of the Medline, CINAHL, CENTRAL and PsycINFO 32 
databases were conducted. Mean content of blood biomarkers from people with clinically-33 
stable CF and non-CF controls were used to calculate the standardized mean difference 34 
(SMD) and 95% confidence intervals (95% CI).  35 
Results: Forty-nine studies were eligible for this review including a total of 1,792 people 36 
with CF and 1,675 controls. Meta-analysis revealed that protein carbonyls (SMD: 1.13, 95% 37 
CI: 0.48 to 1.77), total F2-isoprostane 8-iso-prostaglandin F2α (SMD: 0.64, 95% CI: 0.23 to 38 
1.05) and malondialdehyde (SMD: 1.34, 95% CI: 0.30 to 2.39) were significantly higher, and 39 
vitamins A (SMD: -0.66, 95% CI -1.14 to -0.17) and E (SMD: -0.74, 95% CI: -1.28 to -0.20), 40 
β-carotene (SMD: -1.80, 95% CI: -2.92 to -0.67), lutein (SMD: -1.52, 95% CI: -1.83 to -1.20) 41 
and albumin (SMD: -0.98, 95% CI: -1.68 to -0.27) were significantly lower in the plasma or 42 
serum of people with CF versus controls. 43 
Conclusions: This systematic review and meta-analysis found good evidence for reduced 44 
antioxidant capacity and elevated oxidative stress in people with clinically-stable CF. 45 
Words: 198 of 200 46 
 47 
 48 
 49 
 50 
Keywords: Biological markers; glutathione; minerals; oxidoreductases; redox imbalance; 51 
respiratory disease; vitamins. 52 
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INTRODUCTION 53 
Cystic fibrosis (CF) is a multi-system, life-shortening, autosomal recessive disease affecting 54 
more than 70,000 people globally. The disease occurs as a result of mutations in the gene 55 
encoding for the CF transmembrane conductance regulator (CFTR), the primary function of 56 
which is the efflux of chloride and bicarbonate anions. CFTR is commonly expressed within 57 
the epithelial cells that line the mucous membrane and submucosal glands of the airway [1]. 58 
Dysfunctional CFTR results in inflammation [2] and airway infection, a progressive decline 59 
in lung function [3] leading to respiratory failure and premature death [4]. CFTR is also 60 
expressed within various other bodily systems, including the gastrointestinal tract, pancreas, 61 
sweat ducts, skeletal muscle, cardiovascular and reproductive organs [5]. CF is, therefore, a 62 
complex multisystem condition requiring repeated comprehensive assessments to monitor for 63 
and treat disease complications. 64 
Transient increases in free radicals derived from oxygen (reactive oxygen species) and 65 
nitrogen (reactive nitrogen species) activate various physiological signalling cascades that are 66 
beneficial for cellular function and communication [6]. However, several CF co-morbidities, 67 
including lung disease [7], inflammation [8], systemic hypoxaemia [9,10] and dysglycaemia 68 
[11] lead to the exacerbated production of reactive oxygen species exceeding the levels 69 
required for optimal physiological function. CFTR has also been implicated in the efflux of 70 
the main non-enzymatic antioxidant, reduced glutathione (GSH) [12]. Therefore, a loss of 71 
CFTR function in vitro leads to an increased accumulation of intracellular GSH, which blunts 72 
the response to redox-sensitive signalling pathways that modulate adaptations to hypoxia [13] 73 
and cigarette smoke [14], and may render extracellular compartments more susceptible to 74 
oxidative stress [15]. In addition to this, polymorphisms of the glutathione S-transferase 75 
(GST) and the glutamate-cysteine ligase genes are likely to further deplete extracellular 76 
synthesis and the detoxification potential of GSH [12,16,17]. Together, these factors in 77 
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addition to the malabsorption of micronutrients with antioxidant properties in CF [18], causes 78 
an imbalance between oxidants and antioxidants in favour of oxidants (i.e. oxidative stress), 79 
the disruption of redox signalling and molecular damage [6]. 80 
Whilst the study of CF-related redox imbalances dates back as far as 1967 [19] and has been 81 
the topic of several narrative reviews [15,20,21], a recent meta-analysis highlighted the 82 
potential significance of these imbalances when considering disease pathophysiology [22]. 83 
Van t’ Erve et al. [22] observed that a biomarker of lipid peroxidation, F2-isoprostane 8-iso-84 
prostaglandin F2α (8-iso-PGF2α), was higher in CF compared to other diseases, including 85 
lifestyle factors and environmental exposures which are conventionally characterised by 86 
oxidative stress, such as tobacco smoking and cardiovascular disease [22]. Whilst this review 87 
identified some evidence for increased oxidative stress in CF, the range of biomarkers 88 
considered was limited [23]. 89 
Recent advances in analytical methodologies mean that previously inaccessible biomarkers, 90 
including those used to quantify oxidative damage in biological samples, are now more 91 
widely available for medical and physiological research purposes [24]. Similarly to elevated 92 
8-iso-PGF2α and malondialdehyde (MDA) being indicative of lipid peroxidation, oxidative 93 
modifications to proteins and DNA can be investigated by quantifying protein carbonyl 94 
groups and 8-hydroxy-20-deoxyguanosine (8-OHdG), respectively [25]. In addition to 95 
investigating the end-product of oxidative damage, it is also now possible to characterise 96 
antioxidant deficiencies that might be suitable therapeutic targets. It is recommended that 97 
vitamin and trace element concentrations are monitored in CF clinics [26]; however, from an 98 
antioxidant-perspective it is also useful to quantify thiols, such as GSH and cysteine (Cys), as 99 
these molecules are essential to understanding the redox potential (Eh) of biological fluids 100 
[6]. The content and activity of oxidoreductases, such as superoxide dismutase (SOD), 101 
catalase (CAT) and glutathione peroxidase (GPx), provide additional functional information 102 
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regarding the maintenance of thiol:disulfide couples and are promising therapeutic targets 103 
[27]. Despite the array of available biomarkers to study redox imbalances, there is no 104 
systematic evidence to suggest that oxidative stress occurs as a consequence of lowered 105 
antioxidants in the blood. 106 
Therefore, a systematic search of the existing evidence base from investigations of CF-related 107 
redox imbalances is needed to provide comprehensive and contemporary recommendations 108 
for subsequent clinical practice and research trials. This review aimed to summarise the 109 
literature investigating whether redox abnormalities are present in the blood of people with 110 
clinically-stable CF. We hypothesised that: (1) blood markers of antioxidant status would be 111 
lowered in people with clinically-stable CF compared to non-CF controls, and (2) blood 112 
markers of oxidative stress would be elevated in people with clinically-stable CF compared to 113 
non-CF controls. 114 
 115 
METHODS 116 
Protocol registration 117 
The review protocol was registered on PROSPERO (Reference: CRD42018094241; 118 
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018094241).  119 
Eligibility criteria 120 
Included studies reported blood biomarkers of oxidative stress and/or antioxidant status in 121 
humans with CF, and were compared to a non-CF control group. We included population-122 
based studies with a case-control comparison and intervention trials which had a case-control 123 
comparison at baseline. A clinical diagnosis of CF must have been supported by an abnormal 124 
sweat test, diagnostic genotyping and/or the participant being recruited through a CF clinic. 125 
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Study participants must have been classed as clinically-stable and free from symptoms of an 126 
acute respiratory exacerbation at the time of testing, as this is a commonly accepted source of 127 
antioxidant deficiency and oxidative stress [28]. Studies were excluded if they were review 128 
articles, case reports or letters to the editor. Studies which compared results from individuals 129 
with CF versus standard values derived from the literature were excluded. There was no 130 
restriction on the type of redox-related biomarker; however, it must have been analysed in 131 
blood as CF is associated with renal disease [29] and pelvic floor incontinence [30], both of 132 
which may mean local inflammation alters the redox state of urine. There were no restrictions 133 
on publication period. Studies were excluded if the full-text was not available in English or 134 
French.  135 
Information sources 136 
Extensive searches of the Medline, Current Nursing and Allied Health Literature (CINAHL), 137 
Cochrane Central Register of Controlled Trials (CENTRAL) and PsycINFO databases were 138 
conducted to identify eligible studies up to 9th October 2019. 139 
Searches 140 
In accordance with similar systematic reviews in this area [31], the current review utilised a 141 
three-part search process to identify studies matching the eligibility criteria. The first strategy 142 
used Medical Subject Heading (MeSH) or subject terms, as follows: “cystic fibrosis”[MeSH] 143 
AND (antioxidants[MeSH] OR oxidoreductase[MeSH] OR vitamins[Pharmacological 144 
Action] OR oxidants[MeSH] OR “oxidative stress”[MeSH] OR " lipid peroxidation”[MeSH]) 145 
AND blood[subheading]. When compared to the eligibility criteria, 11 independent and 146 
eligible studies provided a list of 16 common biomarkers in plasma, serum, erythrocyte or 147 
whole blood samples. These data were then utilised to inform the second phase of the 148 
literature search. 149 
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The second strategy identified references based on specific words found within the title 150 
and/or abstract (ti/ab). In this search, the biomarkers and biological substances identified in 151 
the MeSH search were AND-linked to “cystic fibrosis”, as follows: “cystic fibrosis”[tiab] 152 
AND (tocopherol[tiab] OR carotene[tiab] OR malondialdehyde[tiab] OR MDA[tiab] OR 153 
“thiobarbituric acid reactive substances”[tiab] OR TBARS[tiab] OR ascorb*[tiab] OR 154 
lycopene[tiab] OR “protein carbolyl”[tiab] OR copper[tiab] OR isoprostane[tiab] OR 155 
prostaglandin[tiab] OR glutathione[tiab] OR hydroperoxide[tiab] OR superoxide[tiab] OR 156 
SOD[tiab] OR vitamin[tiab] OR zinc[tiab]) AND (blood[tiab] OR plasma[tiab] OR 157 
serum[tiab] OR erythrocyte[tiab] OR “whole blood”[tiab]). The MeSH search was also 158 
repeated at this stage to ensure a broad, specific and sensitive search [32].  159 
The full search terms and strategies of the present review have been published on 160 
PROSPERO (Reference: CRD42018094241). Additionally, bibliographies of included 161 
studies and known review articles, clinical trial registers and conference proceedings were 162 
hand-searched by authors. Experts in the field (identified by the lead authors in published 163 
studies) were contacted to find unpublished trials. 164 
Study selection 165 
The screening and selection process followed two steps and was completed independently by 166 
two authors (AJC and ZLS). After removing duplicate articles, the ti/ab of all references were 167 
screened to identify whether the study met the eligibility criteria, with exclusion of ineligible 168 
articles. Full-texts of the remaining references were subsequently retrieved and compared 169 
with eligibility criteria. All eligible references were included in the systematic review (Table 170 
1). Meta-analyses were only conducted on outcomes which were reported by a minimum of 171 
two independent studies. If a biomarker was the subject of two references by the same 172 
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laboratory, only the most recent reference was included for meta-analysis. These 173 
methodologies have been used in similar meta-analyses [31,33]. 174 
Data collection process 175 
Two review authors (AJC and ZLS) used a review-specific form to independently extract 176 
relevant data on study design, study population, medications, eligibility criteria, biomarkers 177 
and biological fluids studied, and location. Details of the participants (both case and controls) 178 
were recorded where possible, such as information on age, sex, genotype, lung function, co-179 
morbidities and treatments. When available, we extracted data on subgroups, including those 180 
stratified by severity, genotype or co-morbidities. Data was extracted from graphs using plot 181 
digitizer software. Where data and/or measures of variability were not available within a 182 
manuscript, this was either calculated or requested from the corresponding author. If data was 183 
not made available, the reference was included in the systematic review but excluded from 184 
the meta-analysis.  185 
Assessment of quality and risk of bias of included studies 186 
Two review authors (AJC and ZLS) independently assessed the quality of studies using the 187 
Newcastle-Ottawa Quality Assessment Scale (NOS) for Case-Control Studies [34]. To 188 
minimize bias in the interpretation of the scale, both authors independently assessed 10 189 
unrelated studies not included in the present review, whereby disparities in judgements were 190 
discussed and a consensus was reached prior to the assessment of studies included in the 191 
present review. Each study was graded for selection, comparability and exposure, and could 192 
be awarded a maximum of 9 points. Studies scoring 0-2 were considered low quality, studies 193 
scoring 3-5 were considered moderate quality and studies scoring 6-9 points were considered 194 
high quality [33]. Risk of publication bias was assessed at the outcome level using a funnel 195 
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plot [35], which was tested for asymmetry. These methodologies have been used in similar 196 
meta-analyses [31,33]. 197 
Measures of the group effect 198 
Measures of the group effect were calculated using the RevMan v5.3 (Cochrane, UK) 199 
software [36]. For each study, mean differences and 95% confidence intervals (CI) were 200 
calculated [36]. Given that biomarkers were consistently expressed to different units or 201 
analysed using different methodologies, standardized mean differences (SMD) were 202 
calculated. 203 
Assessment of heterogeneity in included studies 204 
Assessments of heterogeneity were calculated using the RevMan v5.3 (Cochrane, UK) 205 
software [36]. In the present review, the I2 statistic was used to assess heterogeneity. The I2 206 
statistic provides a percentage value that represents the variability in effect estimates that is 207 
due to heterogeneity. An I2 of ≥ 75% suggests considerable heterogeneity [36]. In the 208 
presence of considerable heterogeneity, which could be explained by methodological or 209 
population-based considerations, a random-effects model was incorporated using The 210 
DerSimonian-Laird method [37]. Data of considerable heterogeneity that could not be 211 
explained by methodological or population-based considerations were excluded from the 212 
meta-analysis. If heterogeneity could not be explained by methodological or clinical factors, 213 
data were not pooled but, instead, reported within the text. These techniques have been used 214 
in similar meta-analyses [31,33]. 215 
Data synthesis 216 
Results of comparable studies were pooled using either fixed-effect or random-effects 217 
models, dependent upon the extent of heterogeneity. 218 
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 219 
RESULTS 220 
 Study Selection  221 
A flow diagram of the screening process is presented in Figure 1. Briefly, after the removal of 222 
duplicate references, a total of 843 references were screened for their eligibility for the 223 
present systematic review. Of the 843 references, 660 were excluded during the ti/ab screen 224 
as they were outside of the scope of the present review. Following the screening of the full-225 
texts (n = 183; n = 10 were excluded as the full-text was not available in English or French), 226 
a further  124 references were excluded because cases were not classified as clinically-stable 227 
(n = 89), there was no eligible control group (n = 21), the study did not include biomarkers 228 
which were within the scope of the present review (n = 13) or the study was not conducted in 229 
humans (n = 1). Consequently, 49 references were eligible for inclusion in the present review 230 
including a total of 1,792 people with CF and 1,675 controls, in which 25 biomarkers were 231 
eligible for meta-analysis (Table 1).  232 
Study Characteristics 233 
A summary of the included references are presented in Table 1. The included studies were 234 
published between 1977 and 2017, and data were collected from 28 centres in Europe, 15 235 
centres in North America, 3 centres in Asia, 2 centres in Oceania and 1 centre in South 236 
America. The majority of studies were of cross-sectional study design (n = 43; 87.8%), along 237 
with data collected at baseline in 2 non-randomized controlled trials (4.1%), 2 non-238 
randomized and non-controlled trials (4.1%), 1 randomized controlled trial (2.0%), and 1 239 
open-pilot observation (2.0%; table 1). The sample sizes of included studies were generally 240 
modest, with the number of cases and controls ranging from 7 to 232 and 6 to 177, 241 
respectively. 242 
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Risk of bias and quality of studies 243 
A summary of the risk of bias assessments is presented in Table 2. Briefly, the quality of the 244 
studies was generally moderate (n = 31; 63.3%), with 14 high (28.6%) and 4 low (8.2%) 245 
quality studies included.  246 
Missing data 247 
Missing data was requested for 7 studies as the mean and/or standard deviation (SD) were not 248 
computable [38–44]; however, no authors provided additional data.  249 
Synthesis of results 250 
Thiols 251 
Twelve eligible studies assayed the content of thiols within the erythrocytes, blood 252 
neutrophils, plasma or serum of people in clinically-stable CF versus non-CF controls. The 253 
biomarkers studied were plasma or serum albumin (n = 6) [45–50], erythrocyte GSH (n = 2) 254 
[39,51], blood neutrophil GSH (n = 2) [40,52] and plasma or serum protein thiol groups (n = 255 
2) [53,54]. 256 
Whilst GSH was studied in blood neutrophils (n = 2) [40,52] and erythrocytes (n = 2) [39,51] 257 
by 4 eligible trials, a meta-analysis was not possible for either biomarker as mean ± SD was 258 
not computable for 2 trials as medians and interquartile ranges were reported [39,40]. The 259 
concentration of albumin in the plasma or serum was significantly lower in people with 260 
clinically-stable CF compared to the non-CF controls (SMD -0.98, 95% CI -1.68 to -0.27, p < 261 
0.01, I2 86%, 6 trials) [45–50]. The concentration of protein thiol groups in plasma or serum 262 
were not significantly different between people with clinically-stable CF and non-CF controls 263 
(SMD -0.35, 95% CI -0.90 to 0.20, p = 0.22, I2 0%, 2 trials) [53,54]. 264 
Vitamins 265 
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Twenty-two studies were eligible and studied the levels of vitamins within the plasma or 266 
serum of people with clinically-stable CF versus non-CF controls. The most studied 267 
biomarkers were related to the fat-soluble vitamins A (inclusive of ‘vitamin A’, ‘retinol’, 268 
carotene, β-carotene, lutein and lycopene; n = 13) [7,41,42,48,49,55–62], E (inclusive of 269 
‘vitamin E’, ‘vitamin E:cholesterol’, tocopherol and α-tocopherol; n = 13) [7,38,41,42,52,54–270 
56,59–64], D (inclusive of ‘vitamin D, ‘25(OH)D’ and ‘1,25(OH)2D’; n = 11) 271 
[44,45,48,50,58–60,65–68] and C (inclusive of ‘vitamin C’, ‘ascorbic acid’ and ‘zeaxanthin’; 272 
n = 5) [7,41,42,57,61]. 273 
The concentration of vitamin A (inclusive of ‘retinol’; SMD -0.66, 95% CI -1.14 to -0.17, p = 274 
0.02, I2 83%, 8 trials; Figure 2) [7,41,49,55,58–62] and β-carotene (inclusive of ‘carotene’; 275 
SMD -2.17, 95% CI -3.30 to -1.03, p = < 0.01, I2 91%, 4 trials) [7,48,55,56] were 276 
significantly lower in the plasma or serum of people with CF compared to the non-CF 277 
controls. The non-provitamin A carotenoids, lutein (SMD -1.52, 95% CI -1.83 to -1.20, p < 278 
0.01, I2 0%, 2 trials) [7,57], lycopene (2 trials; mean ± SD not computable for 1 trial [42], 279 
therefore, meta-analysis was not complete) [7,42] and zeaxanthin (SMD 1.48, 95% CI -5.87 280 
to 8.83, p = 0.69, I2 99%, 2 trials) [7,57] were also studied in plasma or serum samples. The 281 
concentration of vitamin C (inclusive of ‘ascorbic acid’) in the plasma or serum were not 282 
significantly different between people with clinically-stable CF and non-CF controls (SMD -283 
0.05, 95% CI -1.83 to 1.72, p 0.95, I2 93%, 2 trials) [41,61]. The concentration of 25(OH)D 284 
(inclusive of ‘vitamin D’) in the plasma or serum were not significantly different between 285 
people with clinically-stable CF and non-CF controls (SMD -0.23, 95% CI -0.79 to 0.33, p = 286 
0.42, I2 92%, 9 trials; Figure 2) [45,48,50,58–60,66–68]. A metabolite of 25(OH)D, 287 
1,25(OH)2D, has also been studied, however concentrations in plasma or serum were not 288 
different between people with CF and non-CF controls (SMD -0.46, 95% CI -1.12 to 0.20, p 289 
=0.17, I2 90%, 4 trials) [50,65,67,68]. Data were taken from samples collected during winter 290 
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months where possible. The concentration of vitamin E (inclusive of ‘tocopherol’ and ‘α-291 
tocopherol’) in the plasma or serum were significantly lowered in people with CF compared 292 
to their non-CF controls (SMD -0.67, 95% CI -1.13 to -0.21, p < 0.01, I2 87%, 11 trials; 293 
Figure 2) [7,41,54–56,59–64]. However, plasma or serum vitamin E:cholesterol was not 294 
significantly different between people with CF and their non-CF controls (SMD -0.35, 95% 295 
CI -0.03 to 0.74, p = 0.07, I2 0%, 2 trials) [52,54]. 296 
Trace elements 297 
Eight studies were eligible and studied the levels of trace elements within the plasma or 298 
serum of people with CF versus non-CF controls. The trace elements studied were zinc (n = 299 
6) [41,47,49,58,59,69], copper (n = 3) [41,59,70] and selenium (n = 2) [38,41]. 300 
The concentration of copper in the plasma or serum were not significantly different between 301 
people with clinically-stable CF and non-CF controls (SMD 0.53, 95% CI -0.25 to 1.30, p = 302 
0.53, I2 67%, 3 trials) [41,59,70]. The concentration of selenium in the plasma or serum were 303 
significantly lower in people with CF versus the non-CF controls in 1 trial [41], however, a 304 
meta-analysis was not conducted in this biomarker as mean ± SD was not computable for the 305 
second trial [38]. The concentration of zinc in the plasma or serum was not significantly 306 
different between people with CF and non-CF controls (SMD -0.50, 95% CI -1.21 to 0.20, p 307 
= 0.16, I2 89%, 6 trials) [41,47,49,58,59,69].  308 
Oxidoreductases 309 
Five studies were eligible and studied oxidoreductases within the erythrocytes, plasma or 310 
serum of people with CF versus non-CF controls. The oxidoreductases studied were 311 
erythrocyte SOD activity (n = 5) [41,53,61,64,71], erythrocyte CAT activity (n = 2) [53,61] 312 
and plasma or serum ceruloplasmin (n = 2) content [70,71]. 313 
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CAT activity in the erythrocytes were not significantly different between people with CF and 314 
non-CF controls (SMD -0.40, 95% CI -1.51 to 0.72, p = 0.49, I2 78%, 2 trials) [53,61]. 315 
Ceruloplasmin content of the plasma or serum were not significantly different between 316 
people with CF and non-CF controls (SMD 0.60, 95% CI -0.38 to 1.58, p = 0.23, I2 58%, 2 317 
trials) [70,71]. SOD activity in the erythrocytes were not significantly different between 318 
people with CF and non-CF controls (SMD 0.02, 95% CI -1.16 to 1.20, p = 0.97, I2 96%, 5 319 
trials) [41,53,61,64,71].  320 
Total antioxidant capacity 321 
Four studies were eligible and studied the total antioxidant capacity (TAC) (inclusive of total 322 
antioxidant status [TAS] and trolox equivalent antioxidant status (TEAS)) of plasma or serum 323 
in people with CF versus non-CF controls. TAC of the plasma or serum was not significantly 324 
different between people with CF compared and the non-CF controls (SMD -0.82, 95% CI -325 
2.02 to 0.37, p = 0.18, I2 94%, 4 trials) [58,61,72,73]. 326 
Lipid peroxidation 327 
Eleven studies were eligible and studied the levels of lipid peroxidation within the plasma or 328 
serum of people with CF versus non-CF controls. The biomarkers studied were MDA 329 
(inclusive of the thiobarbitoric acid reactive substances [TBARS] assay) (n = 7) 330 
[7,42,54,56,58,61,64,72,74], hydroperoxides (n = 3) [43,64,72] and total 8-iso-PGF2α (n = 3) 331 
[41,58,75].  332 
The concentration of MDA (SMD 1.33, 95% CI 0.43 to 2.24, p < 0.01, I2 96%, 8 trials; 333 
Figure 3) [7,54,56,58,61,64,72,74] and total 8-iso-PGF2α (SMD 0.64, 95% CI 0.23 to 1.05, p 334 
< 0.01, I2 0%, 2 trials; Figure 3) [58,75] in the plasma or serum were significantly higher in 335 
people with clinically-stable CF compared to the non-CF controls (Figure 3). The 336 
concentration of hydroperoxides (SMD 2.80, 95% CI -2.71 to 8.31, p = 0.26, I2 99%, 2 trials; 337 
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Figure 3) [64,72] in the plasma or serum were not significantly different between people with 338 
CF and non-CF controls.  339 
Protein carbonylation 340 
The only biomarker of protein carbonylation studied was plasma or serum protein carbonyls 341 
(n = 4) [42,53,54,64]. The concentration of protein carbonyls in the plasma or serum were 342 
significantly higher in people with CF compared to the non-CF controls (SMD 1.13, 95% CI 343 
0.48 to 1.77, p < 0.01, I2 61%, 3 trials; Figure 3) [53,54,64]. 344 
 345 
DISCUSSION 346 
This systematic review and meta-analysis is the first to investigate whether circulating 347 
biomarkers of antioxidant status and oxidative stress are abnormal in people with clinically-348 
stable CF versus non-CF controls. Forty-nine eligible studies were identified, including a 349 
total of 1,792 people with CF and 1,675 controls, in which 25 biomarkers were eligible for 350 
meta-analysis. Two principal findings were observed: (1) vitamins A and E, β-carotene, 351 
lutein and albumin were significantly lowered in the plasma or serum of people with 352 
clinically-stable CF versus non-CF control participants, and (2) protein carbonyls, total 8-iso-353 
PG2α and MDA were significantly higher in the plasma or serum of people with clinically-354 
stable CF versus non-CF control participants. These data provide systematic evidence that 355 
oxidative stress may be implicated in the pathophysiology of CF even in those who are 356 
clinically-stable and free from a pulmonary exacerbation at the time of sampling. 357 
Thiols 358 
GSH is a tripeptide compound which plays a major role in regulating intracellular redox 359 
balances. In the present review, 4 eligible studies quantified GSH in the erythrocytes [39,51] 360 
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and blood neutrophils [40,52] of people with CF versus controls, however meta-analyses 361 
were not possible due to appropriate data not being reported in 2 of these trials [39,40]. 362 
Notably, neither trial included in the present review reported significant differences in 363 
erythrocyte GSH in people with CF compared to controls [39,51]; however, a significant 364 
negative correlation between erythrocyte GSH and FEV1 was reported in adults with mild-to-365 
very severe CF lung disease [51] (Table 3). Mangione et al. [51] speculated that these 366 
observations reflected the mobilisation of GSH into circulation to neutralize pulmonary ROS 367 
in advanced lung disease. Therefore, it could be suggested that elevated erythrocyte GSH is a 368 
bookmark for historical incidences of oxidative damage in the CF lung [51]. It is unknown 369 
whether other causes of oxidative stress in CF (e.g. CF-related diabetes [CFRD]) contribute 370 
to altered erythrocyte GSH concentrations. 371 
Functional CFTR is permeable to GSH, and defective or deficient CFTR may contribute to 372 
oxidative stress, due to insufficient concentrations of extracellular GSH [12]. No studies were 373 
eligible for the present review that quantified plasma GSH, as GSH is rapidly oxidized in 374 
plasma to form glutathione disulphide (GSSG) [76]. Two studies demonstrated that there 375 
were no differences between plasma protein thiol groups, which are rich in Cys, in people 376 
with CF compared to controls [53,54]. Conversely, plasma or serum albumin, a protein which 377 
constitutes the majority of the plasma protein thiol pool, was significantly lower in people 378 
with CF compared to controls [45–50]. Notably, serum albumin may also be affected in CF 379 
by various co-morbidities including liver disease [77] and malnutrition [78]. Importantly, 380 
only 2 trials that studied circulating thiols reported the genotype of participants [39] and no 381 
trials reported results from a group with a single homozygous genotype. Previous reports 382 
from cell culture have shown that GSH efflux is lowered even in genotypes with residual 383 
CFTR function (classes IV-VI) [17]; however, no studies to date have investigated whether 384 
higher concentrations of extracellular thiols contribute to the improved phenotype often 385 
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observed in class IV-VI genotypes. It is, therefore, important for future studies to control for 386 
the genotype of participants and also investigate differences in thiol concentrations between 387 
subgroups classified by genotype. 388 
An important area for future research is to investigate the thiol:disulphide couples in the 389 
blood of individuals with clinically-stable CF. For instance, Roum et al. [79] demonstrated 390 
that total plasma GSH was ~ 40% lower in people with CF versus healthy controls, however 391 
this study was excluded from the present review as it was unclear whether included cases 392 
were clinically-stable. In a later review, Ziady & Hansen [15] suggested that whilst the GSH 393 
Eh was not significantly different between people with CF and their healthy counterparts in 394 
the study by Roum et al. [79] (-139 mV vs. -138 mV, respectively), the lower concentration 395 
of GSH meant that an acute oxidative pertubation would affect GSH Eh to a greater degree in 396 
those with CF versus healthy controls [15]. However, to fully understand the redox potential 397 
of thiols within plasma of people with CF, other thiol:dilsufide couples must be considered, 398 
including Cys [80] and thioredoxin [81]. No studies to date have investigated the Cys:Cyss in 399 
people with CF. Importantly, whilst extracellular Cys pools are a key regulator of GSH 400 
synthesis, GSH:GSSG and Cys:cystine (Cyss) may have independent functions. For instance, 401 
a lowered Cys:Cyss ratio causes mitochondria-derived ROS generation, which subsequently 402 
activates the key antioxidant transcriptional factor, nuclear factor erythroid 2-related factor 2 403 
(Nrf2) [82]. Interestingly, pharmacological inhibition of CFTR in cellular models causes 404 
lowered expression of Nrf2 in the lung epithelium [83]; therefore, thiol perturbations could 405 
contribute to the accumulation of cytotoxic reactive oxygen species in CF. 406 
Micronutrients 407 
Important sources of exogenous antioxidants are the consumption of water- and fat-soluble 408 
vitamins. In terms of water-soluble micronutrients, vitamin C content was not significantly 409 
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different between people with CF and controls; however, this was only addressed by 2 trials 410 
of moderate-to-high quality [41,61]. Importantly, Madarasi et al. [61] reported significantly 411 
elevated vitamin C in children with CF compared to age-matched healthy controls; however, 412 
participants enrolled on this study were administered 100-200 mg/d of ascorbic acid. 413 
Conversely, Wood et al. [41] reported significantly lowered concentrations of vitamin C in 414 
adolescents with CF who refrained from multivitamin supplementation for 4 weeks prior to 415 
sampling versus age- and sex-matched healthy controls. Fat-soluble micronutrients, vitamin 416 
A [7,41,49,55,58–62], β-carotene [7,48,55,56], lutein [7,57] and vitamin E [7,41,55,56,59–417 
64] were significantly lowered in the plasma or serum of people with CF versus controls, 418 
whilst 25(OH)D [45,48,50,58–60,66–68], 1,25(OH)2D [50,65,67,68] and vitamin 419 
E:cholesterol [52,54] were not significantly different. Importantly, there was a considerable 420 
degree of heterogeneity in the analysis of both water- and fat-soluble micronutrients, likely 421 
caused by differences in the studied population (i.e. age, sex and genotype), differences in 422 
measurement units and supplementation protocols (in addition to adherence variability [18]).  423 
Interestingly, Wood et al. [41] found significant negative correlations between lipid 424 
peroxidation biomarkers and vitamins C, E, and β-carotene (Table 3). It was speculated that 425 
the intensified inflammatory-induced free radical production may result in a depletion of 426 
antioxidant defences in non-supplemented CF participants [41]. Furthermore, vitamins C and 427 
E were positively correlated with prognostically relevant clinical outcomes, such as FEV1 and 428 
the Shwachman-Kulzycki score (Table 3). Multivitamin supplementation is a logical strategy 429 
to increase antioxidant pools in the blood of people with CF and is recommended by The 430 
European Society for Clinical Nutrition and Metabolism [26]. However, increasing the 431 
concentrations of antioxidant vitamins is challenging in this population due to suboptimal 432 
dosing, poor adherence to treatment or nutrient malabsorption [18]. The high treatment 433 
burden of CF, and the subsequent poor adherence to oral supplements, is a considerable 434 
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challenge when developing interventions to mitigate oxidative stress, which is evidenced by 435 
the conflicting evidence regarding micronutrient supplementation for the management of CF 436 
lung disease [84].  437 
In addition to water- and fat-soluble vitamins, various trace elements in blood have direct 438 
antioxidant abilities as well as mediating the activity of oxidoreductases. Only 8 included 439 
studies investigated trace element levels in the blood of people with clinically-stable CF. The 440 
concentration of plasma or serum copper [41,59,70] and zinc [41,47,49,58,59,69] were not 441 
different between people with CF and controls. Furthermore, whilst it was not possible to 442 
conduct meta-analysis on selenium, neither of the included trials reported a significant 443 
difference between the CF and control groups [38,41]. Two trials reported correlations 444 
between zinc and clinically relevant outcomes, including positive relationships with lung 445 
function, nutritional status and interleukin-2 (Table 3) [47,69]. These data suggest that 446 
suboptimal zinc content may be observed in those with more severe lung disease and/or 447 
malnutrition. However, whether this contributes to cases of oxidative stress is currently 448 
unknown and warrants further investigation.  449 
Oxidoreductases 450 
In addition to thiol groups and the exogenous micronutrients, blood also contains antioxidant 451 
defence enzymes that have direct antioxidant effects as well as catalysing reactions which 452 
maintain thiol:disulfide ratios, which limits the development of oxidative stress [6]. The most 453 
studied of these enzymes, SOD, was investigated in 5 trials included in the present systematic 454 
review [41,53,61,64,71]. However, meta-analysis demonstrated that there were no significant 455 
differences in erythrocyte SOD activity between those with CF and controls [41,53,61,64,71]. 456 
Notably, there was a large variability in the results of the included trials, with 2 457 
demonstrating lowered [71,85], 2 indifferent [41,53] and 1 elevated [64] erythrocyte SOD 458 
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activity in the CF group versus controls. Whilst the cause for such variable results is 459 
unknown, the only trial showing elevated erythrocyte SOD activity in CF did not use a 460 
methodology that expressed data relative to haemoglobin or red blood cell count [86]. While 461 
it was not possible to quantify iron deficiencies in the present review, iron deficiency is 462 
reported in 64% of clinically-stable adults with CF [87] and iron supplementation is 463 
recommended in those with persistent inflammation [26]. Therefore, it is possible that the 464 
inconsistent result of elevated erythrocyte SOD activity in people with CF is due to 465 
haemoglobin abnormalities and/or iron supplementation (data regarding nutritional 466 
intake/supplementation was not reported) [64]. It is important to note, however, that no 467 
correlations were observed between erythrocyte SOD activity and a biomarker of lipid 468 
peroxidation in children with CF [85]. Therefore, given these results, it remains unclear 469 
whether circulatory SOD activity has a role in the pathophysiology of CF. 470 
Other oxidoreductases included in the present review’s meta-analyses were erythrocyte CAT 471 
activity and plasma/serum ceruloplasmin content. Notably, there were no differences in 472 
erythrocyte CAT activity [53,61] or plasma/serum ceruloplasmin content [70,71] in people 473 
with clinically-stable CF compared to controls. However, both of these biomarkers were 474 
studied by only 2 trials that were of moderate-to-high quality, but contained modest sample 475 
sizes. Furthermore, trials have documented normal plasma and whole blood GPx activity 476 
[52,58,85], lowered plasma diamine oxidase activity [71], elevated serum GSTα [88], 477 
elevated serum GSTα subunit 1 (GSTα1) content [89], elevated erythrocyte glutathione 478 
reductase (GR) activity [64], and normal serum γ-glutamyl transferase (GGT) content [46]. 479 
However, these biomarkers were not the subject of meta-analysis either due to being studied 480 
by only a single trial or by two or more trials from the same laboratory. Further research is 481 
required to understand whether, or not, circulating oxidoreductases are suitable therapeutic 482 
targets.  483 
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Lipid peroxidation 484 
A vulnerability to lipid peroxidation has been associated with reduced longevity of life in 485 
non-CF populations [90]. Despite the suggested clinical importance of lipid peroxidation in 486 
the pathophysiology of various chronic diseases, the poor specificity of biomarkers is often 487 
described as a limiting factor in the study of oxidative stress [91]. However, the emergence of 488 
8-iso-PGF2α, a lipid peroxidation product of arachidonic acid, as a biomarker of oxidative 489 
stress has vastly improved the progression of the field [92]. 490 
Despite a wealth of research investigating 8-iso-PGF2α levels in human disease [22], the 491 
present review revealed only 2 independent studies eligible for meta-analysis [58,75], both of 492 
which were of high quality (Table 2). Whilst total 8-iso-PGF2α was significantly increased in 493 
people with CF versus controls (Figure 3), neither study reported concentrations of free 8-iso-494 
PGF2α, which would allow the conclusion of increased lipid peroxidation as opposed to the 495 
simultaneous activity of the inflammatory-induced prostaglandin-endoperoxide synthases 496 
[93]. This is important, as a recent meta-analysis summarizing the levels of total and free 8-497 
iso-PGF2α in human disease demonstrated a greater response of free 8-iso-PGF2α in CF 498 
(including those who are classified as unstable) versus controls, suggesting that the increased 499 
concentrations of 8-iso-PGF2α may be a result of non-specific production [22]. 500 
The most studied biomarker of lipid peroxidation in CF was MDA in plasma or serum, which 501 
was the topic of 8 trials eligible for meta-analysis [7,54,56,58,61,64,72,74]. Meta-analysis 502 
observed significantly elevated concentrations of MDA in the plasma or serum of people with 503 
CF versus controls, albeit with a large degree of heterogeneity (Figure 3). Notably, 5/8 of the 504 
trials measured MDA using thiobarbituric acid based assays [56,58,64,72,85]; however, the 505 
use of these assays in complex biological samples is cautioned against as many compounds 506 
within blood react with thiobarbituric acid to produce coloured adducts that could be 507 
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mistaken for elevated lipid peroxidation [94]. In contrast, the present review demonstrated 508 
that concentrations of lipid hydroperoxides in the plasma or serum of people with CF versus 509 
controls were not different; however, meta-analysis was only conducted on 2 trials and a 510 
large degree of heterogeneity limited the results (Figure 3). 511 
Interestingly, lipid peroxidation biomarkers were positively correlated to blood monocyte, 512 
neutrophil and white cell counts (Table 3). These correlations suggest that elevated total 8-513 
iso-PGF2α is associated with exacerbated immune stresses and inflammation that 514 
characterises CF-lung disease. Indeed, chronic bacterial colonization of the CF airway leads 515 
to a dysregulated cycle of inflammation and redox dysregulation [95], which subsequently 516 
leads to cases of oxidative stress [53]. There was not sufficient data to conduct subgroup 517 
analysis of 8-iso-PGF2α content in participants with varying degrees of lung disease. 518 
However, it must be noted that there was no significant correlations between total 8-iso-519 
PGF2α and FEV1 in people with mild-to-moderate CF lung disease [41,75]. Importantly, 520 
authors state that whilst spirometry assesses previous lung damage from infection, transient 521 
increases in 8-iso-PGF2α may reflect the current pathophysiological state of the lung [96]. 522 
Therefore, future trials investigating longitudinal changes in blood 8-iso-PGF2α alongside 523 
spirometry may be of interest to determine whether this biomarker is a suitable target for 524 
redox-based therapeutics. 525 
Various non-pulmonary consequences of CF have also been suggested to contribute to lipid 526 
peroxidation, such as CF-related dysglycaemia [11]. Specifically, exocrine pancreatic 527 
insufficiency and variable insulin resistance lead to the development of CFRD in ~35% of 528 
adults with CF [4], which is associated with greater declines in lung function [97], nutritional 529 
status [98], exercise capacity [99] and prognosis [100]. It was not possible to conduct sub-530 
group analysis on lipid peroxidation biomarkers in people along the dysglycaemic spectrum 531 
of CF, and no correlations between lipid peroxidation and glycaemic control were reported by 532 
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included studies. No studies to date have investigated the content of 8-iso-PGF2α in CFRD. 533 
Instead, Ntimbane et al. [11] described significantly increased concentrations (+109%) of 4-534 
hydroxynonenal (HNE)-protein adducts in people with CFRD vs. their CF-counterparts with 535 
normal glucose tolerance. Oxidative stress, in vitro, is also implicated in pancreatic β-cell 536 
dysregulation, and thus, reduced insulin secretion [101]. Therefore, whilst defective CFTR 537 
contributes to oxidative stress in CF, it is likely that the dysregulation of various 538 
inflammatory-redox cycles also exacerbates cellular damage and contributes to a worsened 539 
phenotype (e.g. the progression from impaired glucose tolerance to CFRD) [101]. 540 
Whilst the present meta-analysis does provide preliminary evidence that lipid peroxidation is 541 
elevated in the blood of clinically-stable people with CF, further high-quality research is 542 
required to improve the clarity of our understanding. Prospective observational trials should 543 
quantify free and total 8-iso-PGF2α in CF versus healthy control participants. Such data 544 
would further the rationale to investigate redox-based therapeutics in CF. In other chronic 545 
health conditions, non-pharmaceutical interventions to inhibit lipid peroxidation include 546 
dietary and lifestyle modifications (e.g. physical activity promotion), and supplementation of 547 
various extracts, oils and juices (e.g. green tea extract); however, such strategies are yet to be 548 
investigated in people with CF [102]. 549 
Protein carbonylation 550 
Oxidative damage of proteins has been linked with the pathophysiology of many diseases and 551 
is most commonly quantified by the determination of protein carbonyls [6]. A number of 552 
radical species, including hydrogen peroxide and peroxynitrous acid, readily oxidize amino 553 
acid residues to form carbonyl groups. The present review observed significantly elevated 554 
concentrations of protein carbonyls in the plasma or serum of people with CF versus controls 555 
(Figure 3). However, included studies did not report correlation coefficients between protein 556 
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carbonyls and clinically relevant outcomes. In other chronic health conditions, oxidative 557 
damage to proteins is a significant contributor to skeletal muscle dysfunction [103], with 558 
reports showing elevated concentrations of protein carbonylation and nitration in the blood 559 
and skeletal muscle of people with chronic obstructive pulmonary disease [104]. Such 560 
associations could have implications in the skeletal muscle dysfunction which characterise 561 
CF [105]. 562 
It has been suggested that peripheral skeletal muscle dysfunction in CF  may be a 563 
consequence of reduced skeletal muscle mass due to nutrient malabsorption, physical 564 
inactivity and inflammation, but also a defect in skeletal muscle oxidative metabolism 565 
[106,107]. More recently, redox disturbances have been suggested to contribute to exercise 566 
intolerance in CF [108]. Tucker et al. [108] used electron paramagnetic resonance 567 
spectroscopy to determine alkoxyl radical formation during a single bout of submaximal 568 
cycling in adolescents with CF (FEV1 93 ± 16% predicted) versus age- and sex-matched 569 
healthy controls. It was discovered that whilst circulating protein carbonyls and total 8-iso-570 
PGF2α were not significantly different at baseline or during exercise (notably, in a small 571 
sample of adolescents with only mild CF lung disease), there was a significant increase in 572 
alkoxyl radical production during exercise in the CF group only [108]. However, the sources 573 
for an exacerbated production of ROS during exercise in people with CF are unknown. 574 
Defective CFTR has been associated with mitochondrial defects [109], whereby several 575 
studies have reported a reduced activity of the mitochondrial complex I in CF cells [110–576 
112], potentially due to mitochondrial GSH depletion [113], and complex V in CF mice 577 
(F508del) [114]. However, a marker of mitochondrial oxidative stress, aconitase, was not 578 
different in skeletal muscle subsarcolemmal or interfibrillar mitochondria between CF and 579 
control mice [114]. Other key non-mitochondrial sources of reactive oxygen species that 580 
could contribute to the oxidative modification of protein during exercise are NADPH 581 
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oxidase, xanthine oxidase and phospholipase A2 [115]. However, these enzyme complexes 582 
are yet to be studied in models of CF skeletal muscle. It is, therefore, not clear whether redox 583 
imbalances are a suitable therapeutic target to improve mitochondrial function and/or skeletal 584 
muscle oxidative capacity in CF. This represents an important avenue for future research. 585 
Whilst the present meta-analysis does provide preliminary evidence that protein 586 
carbonylation is elevated in the blood of clinically-stable people with CF, further research is 587 
required to improve the clarity of our understanding. Prospective observational trials should 588 
identify relationships between protein carbonylation biomarkers and clinically relevant 589 
outcomes. 590 
Limitations 591 
The present systematic review and meta-analysis had several inherent limitations. At present, 592 
there are significant gaps in the literature investigating whether age, sex and genotype affect 593 
redox biomarkers. From the correlations reported by the studies included in this review, it 594 
appears that antioxidants have a negative, but oxidative stress biomarkers have a positive 595 
relationship with age. However, longitudinal studies are required to confirm these 596 
associations. A limiting factor of the present review was a high degree of heterogeneity in the 597 
majority of biomarkers, which might be explained by only 10/49 studies having matched 598 
cases and controls by age and one other factor (Table 2). We, therefore, recommend that 599 
future trials must match controls and cases by at least age and, preferably, sex. Other sources 600 
of heterogeneity include variations in the methodology of the assays and units of measure. 601 
Another important limitation is the age of some of the included studies. Due to advances in 602 
medicine, the survival age of people with CF has substantially increased since the oldest 603 
included study in 1977. Furthermore, ground breaking treatments, such as CFTR modulators 604 
that alter the negative consequences of CFTR mutations at a molecular level, are becoming 605 
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mainstream treatment options. It is unknown whether the redox imbalances observed in the 606 
present review would persist following CFTR modulator treatment, and this is also an 607 
important area for future research. 608 
Future research directions 609 
The present review focussed upon antioxidant and oxidative stress biomarkers that were 610 
sampled whilst the cases with CF had clinically-stable lung disease (i.e. not hospitalised). In 611 
addition to increased lung infection and inflammation [116], CF-related pulmonary 612 
exacerbations are also associated with the development of acute dysglycaemia even in cases 613 
with normal glucose tolerance [117], increased muscle weakness and weight loss in 614 
bedbound patients [118,119], and hypovitaminosis of antioxidant micronutrients [28]  - all of 615 
which may increase biomarkers of oxidative damage [6]. Furthermore, whilst the treatment of 616 
pulmonary exacerbations may lead to increased antioxidant vitamin content of the blood 617 
plasma [120], evidence of elevated lipid peroxidation and protein carbonylation persist 618 
despite significant improvements in lung function [120,121]. Therefore, it would be of 619 
interest for future trials to investigate whether such redox imbalances following the treatment 620 
of acute pulmonary exacerbations are associated with clinically relevant outcomes, such as 621 
time until the next hospitalization.  622 
Various biomarkers which are important to understand oxidative stress in vivo have not yet 623 
been studied on a case-control basis in the blood of people with clinically-stable CF. DNA 624 
oxidation can be quantified by circulating 8-OHdG. Systematic evidence suggests blood 8-625 
OHdG is elevated in cardiovascular disease [122]. Furthermore, elevated blood 8-OHdG is 626 
associated with poorer prognosis in people with metabolic [123], cardiovascular [124,125] 627 
and neurodegenerative [126] diseases. Elevated urinary 8-OHdG has been documented in 628 
adolescents with mild to severe CF lung disease versus age-matched controls [127]. 629 
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Additionally, urinary 8-OHdG was positively associated with plasma α-tocopherol, but a 630 
significant correlation was not observed with FEV1 [127]. However, various co-morbidities 631 
of CF, such as renal disease, are becoming increasingly common [29]. These co-morbidities 632 
may cause local inflammation that could reduce the ability of urinary samples to provide 633 
systemic indices of oxidative stress. Therefore, it would be useful to confirm these findings in 634 
blood samples. 635 
Another increasingly recognised co-morbidity of CF is micro- [128] and macrovascular [129] 636 
endothelial dysfunction [130], which may be accentuated by the development of 637 
dysglycaemia [131]. Cell culture studies have demonstrated that CFTR is expressed in 638 
endothelial cells from the human pulmonary artery [132,133], lung microvasculature [134] 639 
and umbilical vein [134], which normally limits, but in CF may exacerbate, the production of 640 
pro-inflammatory and pro-oxidant pathways [130]. Previous research has demonstrated that 641 
acute treatment of CF participants with antioxidants (1,000 mg vitamin C, 600 IU vitamin E, 642 
and 600 mg α-lipoic acid) [135] or tetrahydrobiopterin (20 mg/kg) [136] improved 643 
endothelial function measured by flow mediated dilation. These data implicate both oxidative 644 
stress and a reduced bioavailability of the potent vasodilator, nitric oxide, in CF-related 645 
endothelial dysfunction. Notably, in circumstances of oxidative stress, superoxide readily 646 
oxidises nitric oxide to form peroxynitrite. Therefore, it would be useful for future studies to 647 
quantify levels of nitrotyrosine (a biomarker of nitrosative stress by reactive nitrogen species, 648 
including peroxynitrite) in the blood of clinically-stable people with CF versus controls. 649 
Notably, previous trials have reported elevated concentrations of nitrotyrosine in the exhaled 650 
breath condensate [137] and sputum [138] of people with CF. 651 
 652 
CONCLUSION 653 
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This review is the first to systematically demonstrate that some, but not all, circulating 654 
biomarkers of antioxidant capacity are lowered and oxidative stress are increased in people 655 
with clinically-stable CF compared to controls. Further research is required to understand the 656 
consequences of oxidative stress upon the pathophysiology of CF-related disorders, such as 657 
lung disease, diabetes mellitus and skeletal muscle abnormalities. 658 
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 1191 
 1192 
 1193 
 1194 
FIGURES AND TABLES 1195 
Figure 1. A CONSORT flow diagram of the study identification, screening and selection 1196 
process. 1 Excluded studies either investigated participants who are not clinically-stable (n = 1197 
12) or does not mention the status of participants (n = 77). MeSH, Medical Subject Headings; 1198 
SH, Subject heading; Ti/ab, title and abstracts. 1199 
 1200 
Figure 2. Forest plot demonstrating the differences in fat-soluble vitamin concentrations in 1201 
clinically-stable people with CF versus non-CF controls. N.b. ‘vitamin A’ is inclusive of 1202 
‘retinol’, ‘25(OH)D’ is inclusive of ‘vitamin D’ and ‘vitamin E’ is inclusive of ‘tocopherol’ 1203 
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and ‘α-tocopherol’. 95% CI, 95% confidence interval; IV, inverse variance; SD, standard 1204 
deviation. N.b. a negative SMD represents a lower vitamin concentration in CF versus 1205 
controls, whereas a positive SMD represents a higher vitamin concentration in CF versus 1206 
controls.   1207 
 1208 
Figure 3. Forest plot demonstrating the differences in biomarkers of oxidative damage in 1209 
clinically-stable people with CF versus non-CF controls. 95% CI, 95% confidence interval; 1210 
IV, inverse variance; SD, standard deviation. N.b. a negative SMD represents a lower vitamin 1211 
concentration in CF versus controls, whereas a positive SMD represents a higher vitamin 1212 
concentration in CF versus controls.   1213 
 1214 
 1215 
 1216 
 1217 
 1218 
 1219 
 1220 
 1221 
 1222 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
AbdulWahab [69], 
cross-sectional 
Doha, Qatar 53 people with cystic fibrosis (CF) (M = 41.5%; 
15.1 ± 9.1 y) from a kindred Arab tribe. 84.9% 
were I1234V homozygous and pancreatic 
sufficient (PS); 15.1% were non I1234V and 
pancreatic insufficient (PI); 35.8% had chronic 
P. aeruginosa colonisation; Mean ± SD forced 
expiratory volume in 1 s (FEV1) was 79.1 ± 
22.2%. All those with PI were administered 
with pancreatic enzyme replacement and 
multivitamin supplements. 17.7% who were PS 
were receiving multivitamins. 
45 healthy control participants 
(HCP) (male (M) = not reported 
(NR); 20.4 ± 10.1 y) were recruited 
from the same kindred Arab tribe. 
Plasma albumin (CF 
group only) and 
zinc. 
Olveira [58], 
cross-sectional 
Malaga, Spain 36 people with CF (M = 56.3%; 27.2 ± 8.9 y).  In 
those with frequent exacerbations, bacterial 
colonization and/or FEV1 ≤ 50% predicted, 500 
mg/day of azithromycin was administered 
(63.9%). Of those administered with 
azithromycin, mean ± SD FEV1 was 47.1 ± 21.3% 
and forced vital capacity (FVC) was 60.1 ± 
21.8%; 69.6% were PI; 30.4% had CF-related 
diabetes (CFRD). Of those who were not 
administered with azithromycin, mean ± SD FEV1 
was 77.1 ± 20.9% and FVC was 82.9 ± 17.1%; 
61.5% were PI; 38.5% had CFRD. None were 
receiving dietary supplements with Omega-3 fatty 
acids. 
41 HCP (M = 41.5%; 29.0 ± 9.6) 
matched for nutritional status, sex and 
age. 
Plasma glutathione 
peroxidase (GPx), 
total antioxidant 
capacity (TAC), 
catalase (CAT) and 
superoxide dismutase 
(SOD). Plasma or 
serum F2-isoprostane 
8-iso-prostaglandin 
F2α (8-iso-PG2α), 
Thiobarbituric acid 
reactive substances 
(TBARS), vitamins 
A, D and E, and zinc.  
 
Konstantinidis 
[139], 
cross-sectional 
Thessaloniki, 
Greece 
58 people with CF; 27 with (CFwNP) (M = 
48.1%; 28.5 ± 6.1 y) and 31 without (CFsNP) (M 
= 54.8%; 28.1 ± 6.5 y) nasal polyposis; 25.9% 
were F508del homozygous; 50.0% were F508del 
heterozygous; 24.1% were non-F508del. 32.8% 
had P. aeruginosa colonisation. All CF 
participants were supplemented with 3,000 
IU/day of Vitamin D3. 
62 people with chronic rhinosinusitis; 
32 with (CRSwNP) (M = 53.1%; 29.3 ± 
8.4 y) and 30 without (CRSsNP) (M = 
46.7%; 29.5 ± 5.9 y) nasal polyposis. 
32 HCP (M = 53.0%; 28.2 ± 7.9 y) 
from an outpatient clinic for elective 
nasal or oral surgery. 
Serum 25(OH) VD3. 
Antus [74], 
cross-sectional 
Budapest, 
Hungary 
40 people with CF (M = 60.0%; 25.0 ± 0.9 y); 
50% were F508del homozygous. Mean ± SD 
FEV1 was 54.4 ± 4.0% and FVC was 73.5 ± 
25 HCP (M = 52.0%; 35.8 ± 2.4 y) 
with no evidence of pulmonary disease. 
 
Plasma 
malondialdehyde 
(MDA). 
 Table 1. Characteristics of included studies.  
54 
 
First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
3.4%; 52.5% had P. aeruginosa colonisation. All 
were taking vitamin supplements, pancreatic 
enzyme supplements, inhaled/nebulised β2-
agonists. 31.1% were receiving inhaled 
corticosteroid and 75.6% were receiving 
nebulised DNase. 31.1% were receiving inhaled 
antibiotics at the time of sample collection. 
 
 
Lee [45], 
cross-sectional 
Atlanta, USA 25 people with CF (M = 56.0%; 18.5 ± 14.0 y); 
88% were PI; 48.0% were administered with 
vitamin D supplements. 
28 HCP (M = 21.0%; 29.0 ± 6.0 y) on 
no medications which affect vitamin D 
concentration and metabolism. Vitamin 
D intake was limited to < 1,000 IU/day. 
Serum albumin, total 
and free 25(OH)D 
and vitamin D 
binding protein. 
Turowski [140], 
flaxseed 
supplement non-
randomized and 
non-controlled trial 
 
Philadelphia 
and 
Pennsylvania, 
USA 
10 people with CF (M = 30.0%; 31.9 ± 10.8 y; 
FEV1 76.8 ± 16.8% predicted; body mass index 
(BMI) 22.0 ± 1.8 kg/m2); 70.0% were PI, 80.0% 
taking pancrealipase.   
5 HCP (comparable in age). Plasma enterodiol 
and enterolactone. 
Yadav [59], 
cross-sectional 
Chandigarh, 
India 
21 people with CF (M = 81.5%; 5.7 ± 2.5 y; this 
includes those with an acute respiratory 
exacerbation); 22.2% were receiving pancreatic 
enzyme supplementation.  
27 HCP (M = 70.4%; 7.4 ± 2.7 y) who 
were matched for age and sex. 
Plasma 25(OH)D, 
and vitamins A and 
E. Serum copper, iron 
and zinc. 
Sadowska-Bartosz 
[53], 
cross-sectional 
Rzeszow, 
Poland 
22 people with CF; 12 with chronic P. aeruginosa 
(M = 30.0%; 12.8 ± 7.6 y; BMI 18.7 ± 2.9 kg/m2) 
and 10 with chronic S. aureus (M = 30.0%; 10.2 ± 
3.6 y; BMI 18.6 ± 3.8 kg/m2) infections; 40.1% 
for F508del homozygous. Of those with P. 
aeruginosa colonization, mean ± SD FEV1 was 
71.0 ± 8.7% predicted and FEV1/FVC ratio was 
79.7 ± 20.0%. Of those with S. aureus 
colonisation, mean ± SD FEV1 was 94.2 ± 11.4%, 
and FEV1/FVC ratio was 89.6 ± 17.8%. All were 
PI and receiving pancreatic replacement therapy 
and nebulized DNase. All were receiving 
multivitamin supplements, nutritional drinks, 
inhaled sodium chloride. Those with P. 
aeruginosa were receiving 250 mg azithromycin 
3 days per week. 
11 HCP (M = 45.5%; 11.3 ± 4.5 y; 
BMI 16.7 ± 1.5 kg/m2) who were 
recruited as outpatients without chronic 
disease. FEV1 was 96.5 ± 12.1% 
predicted and FEV1/FVC ratio was 
107.5 ± 5.9%.  
Plasma advances 
glycation end-
products (AGE), 
amadori products,  
advanced oxidation 
protein products  
(AOPP), dityrosine, 
formylkynurenine, 
kynurenine, protein 
carbonyls, thiol 
groups and 
tryptophan. 
Erythrocyte CAT, 
glutathione S-
transferase (GST), 
SOD and TAC. 
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Ambroszkiewicz 
[60], 
cross-sectional 
Warsaw, 
Poland 
35 people with CF (M = 48.6%; median (range), 
7.0 (5-9) y); 60.0% were F508del homozygous; 
29.0% were F508del heterozygous; 11.0% were 
non-F508del. Mean ± SD FEV1 was 89.6 ± 12.2% 
predicted. No participants had CFRD and 2.9% 
had hepatic insufficiency; 94.3% of participants 
were PI, and were receiving pancreatic enzyme 
replacement supplements (6,000 U lipase/kg/day).  
No participants received inhaled or systemic 
corticosteroids 1 month prior to sample 
collection. All participants were supplemented 
with Vitamins A (2,000 IU/day), E (200 IU/day) 
and D3 (400 IU/day) 
35 HCP (M = 48.6%; median (range), 
7.0 (5-9) y) who were matched for age 
and sex. HCP were recruited from an 
outpatient clinic and presented with 
minor problems other than infections 
and diseases which may influence bone 
status. 
Serum 25(OH)D, and 
vitamins A and E. 
Olveira [52], 
cross-sectional 
Malaga, Spain 36 people with CF (M = 50.0%; 27.2 ± 8.9 y). 
Mean ± SD FEV1 was 57.8 ± 25.4% and FVC 
was 68.2 ± 22.8%; 86.1 were colonized with P. 
aeruginosa and mean ± SD exacerbations for the 
past year was 2.4 ± 2.0. None were receiving 
Omega-3 fatty acid supplements.  
50 HCP (M = 25.0%; 12.8 ± 7.6 y); 54 
non-CF bronchiectasis (M = 29.7%; 
47.4 ± 18.9 y). 
Plasma or serum 
copper, selenium and 
vitamin C. Plasma 8-
iso-PG2α, CAT, GPx, 
SOD, TAC and 
TBARS. Serum 
vitamins A, D, 
E:cholerterol and 
zinc. Neutrophil, 
lymphocyte, 
monocyte and total 
leukocyte peroxide, 
superoxide and 
reduced glutathione 
(GSH). 
Bernardi [39], 
cross-sectional 
Sao Paulo, 
Brazil 
44 people with CF (M = 50.0%; 8.4 ± 3.2 y); 
31.8% were F508del homozygous; 68.2% for 
F508del heterozygous; 100% were PI; 6.8% had 
CFRD; 38.6% had hepatic disease. Furthermore, 
25.0% were colonized with S. aureus and 6.8% 
were colonized with P. aeruginosa. 
16 HCP (M = 25.0%; 8.3 ± 2.6 y).  Erythrocyte GSH. 
Sadowska-Woda 
[72], 
AquADEK 
Rzeszow, 
Poland 
50 people with CF (M = 60.0%; 9.6 ± 3.7 y; BMI 
19.3 ± 2.8 kg/m2). Mean ± SD FEV1 was 57.8 ± 
25.4% predicted and FVC was 68.2 ± 22.8%; 
21 HCP (M = 66.7%; 9.6 ± 3.1 y; BMI 
20.1 ± 5.2 kg/m2) who were not 
receiving multivitamin 
Plasma 
hydroperoxides, 
MDA, thiol groups 
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supplementation 
non-randomized 
controlled trial 
100.0% were PI and receiving pancreatic enzyme 
replacement supplements (Creon or Lapancrea). 
Children were receiving daily inhaled DNase. 
supplementation.  Mean ± SD FEV1 
104.2 ± 12.3% predicted and 
FEV1/FVC was 90.0 ± 12.7%. 
and TAC. 
Erythrocyte CAT, 
SOD and thiol 
groups. 
Cobanoglu [66], 
cross-sectional 
Ankara, 
Turkey 
16 people with CF (M = 50.0%; 6.1 ± 1.5 y and 
pre-pubertal); 6.3% were F508del homozygous; 
43.8% were F508del heterozygous; 50.0% were 
non-F508del; 100.0% were PI and receiving 
pancreatic enzyme replacement supplements and 
800 IU/day of vitamin D. Non-had CFRD or liver 
disease. None were receiving anti-epileptic drugs, 
calcium supplements, systemic or inhaled 
steroids. 
16 HCP (M = 50.0%; 6.1 ± 1.4 y) 
admitted to hospital for minor issues 
other than infection and were pre-
pubertal.  
Serum 25(OH)D. 
Durieu [43],  
intravenous fish oil 
n-3 emulsion open-
pilot observation 
Lyon, France 13 people with CF (M = NR; 19.4 ± 11.1 y) prior 
to treatment with intravenous n-3 fatty acids. 
Mean ± SD FEV1 was 81.5 ± 12.8% and 51.0 ± 
15.6% for children and adults, respectively. 
 
21 HCP (M = NR; age range, 20-55 y) 
from a related study [141]. 
Plasma 
hydroperoxides.  
Plasma vitamins A 
and E, carotenoids 
and MDA in CF 
group only. 
van Biervliet [142], 
cross-sectional 
Ghent, 
Belgium 
104 people with CF; separated into two groups, 
(A) class I, II, III (M = 50.6%; median (IQR), 
15.0 (13.4) y), and (B) class IV, V or unknown 
CFTR genotypes (M = 56.0%; median (IQR), 
16.0 (20.0) y). Group A: median (IQR) FEV1 was 
80.4 (40.4)% predicted and FVC 89.7 (21.3)% 
predicted; 100% were PI; 11.4% had CFRD; 
16.5% had liver disease. Group B:  median (IQR) 
FEV1 was 75.0 (41.4)% and FVC 86.7 (21.3)% 
predicted; 32.0% were PI; 19.0% had CFRD; 
8.0% had liver disease. None received 
polyunsaturated fat supplements. PI participants 
received pancreatic enzyme replacement and 
multivitamin supplements (1000 IU 
cholecalciferol, 100 mg α-tocopherolacetate, 1 mg 
phytoimenadion and 10000 IU retionolacetate).  
44 HCP (M = NR; median (range), 
18.0 (1-47) y). 
Serum α-linolenic 
acid, arachidonic 
acid, 
docosahexaenoic 
acid, linoleic acid and 
oleic acid. 
Rovner [67], 
cross-sectional 
Pennsylvania, 
USA 
101 people with CF (M = 50.0%; 14.8 ± 4.2 y). 
FEV1 was 84 ± 19% predicted. None had CFRD. 
177 HCP (M = 42.0; 12.5 ± 3.5 y). Serum 1,25(OH)2D  
and 25(OH)D. 
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All participants were receiving vitamin D and 
pancreatic enzyme supplements. 
Oudshoorn [63], 
cross-sectional 
Utrecht, The 
Netherland 
30 people with CF (M = 53.3; 11.9 ± 2.6 y, range 
8-18 y). FEV1 was 88.5 ± 18.7% predicted. All 
received a mean ± SD 120 ± 75 mg/day α-
tocopherol supplementation. 
30 outpatients (M = 43.3; 11.3 ± 2.9 y) 
who underwent ear, nose or throat 
surgery. 
Plasma α-tocopherol, 
coenzyme 
Q10:cholesterol ratio, 
total, oxidized, 
reduced coenzyme 
Q10. 
Tirouvanziam [40],   
non-randomized 
trial of N-
acetylcysteine 
Stanford, USA 18 people with CF (sex and age NR) prior to 
treatment with N-acetylcysteine. 
9 HCP (sex and age NR). Neutrophil GSH. 
Nicolaidou [44], 
cross-sectional 
Athens, 
Greece 
25 people with CF (M = 50.0; range 6-17 y, 
median (p25, p75), M = 15.0 (14.0, 16.0), F = 
14.5 (11.0, 15.0) y) without a vitamin K 
intervention.  Median (p25, p75) FEV1 was 71.5 
(45, 85)% predicted for males and 75.5 (62, 
104)% predicted for females. No group specific 
genotype data was available. 100.0% were PI and 
receiving pancreatic enzyme replacement 
supplements. None were receiving antibiotics or 
had ever received corticosteroids. All were 
receiving 800 IU/day vitamin D 
25 HCP (M = 52.0; range 8-17 y, 
median (p25, p75), M = 14.0 (12.0, 
16.0), F = 11.0 (9.0, 14.0) y). 
Serum 25(OH)D  and 
vitamin K. 
Back [42], 
cross-sectional 
Tubingen, 
Germany 
22 people with CF (M = 40.9%); separated into 3 
groups for analysis: those who are 7 6-11 y 
(median (IQR), 9.4 (7.7-11.1) y), 7 12-17 y 
(median (IQR), 15.0 (14.0-16.7) y) or 7 ≥18 y 
(median (IQR), 23.6 (19.7-29.0) y); 27.3% were 
F508del homozygous; 45.5% were F508del 
heterozygous; 13.6% were non-F508del. 86.4% 
were PI and 18.2% had CFRD. Median (IQR) 
FEV1 was 90.0 (84.5-102.0)% predicted in those 
6-11 y, 80.0 (63.0-82.0)% predicted in those 12-
17 y and 65.0 (42.0-84.0)% predicted in those 
≥18 y.  FVC was 92.0 (87.0-95.0)% predicted in 
those 6-11 y, 81.0 (71.0-86.0)% predicted in those 
12-17 y and 6588 (65.0-95.0)% predicted in those 
30 HCP (M = 53.3); separated into 3 
groups for analysis: 9 6-11 y (median 
(IQR), 8.4 (7.4-10.3) y), 5 12-17 y 
(median (IQR), 13.3 (12.6-16.4) y) and 
16 ≥18 y (median (IQR), 27.6 (24.5-
30.2) y). 
 
Plasma vitamin E, β-
carotene, β-
cryptoxanthin, 
lycopene, protein 
carbonyls, TBARS 
and vitamin C. 
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≥18 y. 
Best [71],   
randomized 
controlled trial of 
copper 
supplementation 
Columbus, 
USA 
38 people with CF (M = NR; 24.8 ± 8.0 y, range 
12-48 y) before supplementation with copper and 
zinc; 100% had PI and were receiving pancreatic 
enzyme replacement and multivitamin 
supplements (ADEK). None had CFRD, renal 
failure or advanced lung disease.   
30 HCP (age and sex NR). Erythrocyte SOD. 
Plasma ceruloplasmin 
and diamine oxidase 
Lagrange-Puget [7], 
cross-sectional 
Lyon, France Up to 232 people (depending on biomarker 
studied) with CF (M = NR; mean (range), 13.0 
(0.5-45.0) y). All had PI and were receiving 
pancreatic enzyme replacement supplements. 
Those with vitamin A and E deficiency received 
retinol or tocopherol supplements.   
53 HCP (M = NR; mean (range), 22.0 
(1.0-40.0) y); including, 21 children 
admitted for orthopedic surgery (before 
treatment) and 32 healthy individuals 
attending a phase I clinical trial center.  
Plasma α-carotene, β-
carotene, GSH, 
tGSH, lipid 
peroxides, lutein, 
lycopene, MDA, 
TBARS, vitamins A 
and E, and 
zeaxanthin. 
Schupp [57], 
cross-sectional 
California, 
USA 
10 people with CF (M = 90.0; 31.2 ± 10.0 y, 
range 21-47 y). Mean ± SD FEV1 was 45.0 ± 
25.4% predicted. 100% were PI and receiving 
pancreatic enzyme replacement supplements. 
30% had CFRD. All were receiving nutritional 
supplements, however, 10% were receiving 
multivitamin supplements containing lutein.  
10 HCP (age range 20-51 y) matched 
for age, sex and ethnicity.  
Plasma lutein and 
zeaxanthin. 
Sidlova [88], 
cross-sectional 
Prague, Czech 
Republic 
37 people with CF (M = 64.9; mean (range), 10.4 
(1-28) y); 10.8% had hepatobiliary abnormalities. 
27 controls (M = 66.7; mean (range), 
8.5 (2-17) y). 
Serum GSTα 
Aris [68], 
cross-sectional 
North 
Carolina, USA 
50 people with CF (M = 46.0; 28.3 ± 7.8 y); 56% 
were F508del homozygous; 28% were F508del 
heterozygous; 16% were non-F508del. Mean ± 
SD FEV1 was 46.1 ± 18.6% predicted and FVC 
was 67.5 ± 17.9% predicted. 94% were PI and 
were receiving pancreatic enzyme replacement 
supplements; All were receiving multivitamin 
supplementation.  
53 HCP (M = 50.9; 28.9 ± 7.8 y) who 
were matched for age and sex.  
Serum 1,25(OH)2D 
and  25(OH)D. 
McGrath [54], 
cross-sectional 
Belfast, UK 11 people with CF (M = 72.7%; range, 18-37 y). 
All were receiving vitamin E supplementation 
(200 mg/day). None receiving any other 
antioxidants and all non-smokers.  
11 HCP (M = 72.7%; range, 20-35 y). 
All non-smokers.  
Plasma vitamin 
E:cholesterol, 
MDA:cholesterol, 
protein carbonyls and 
protein thiols.  
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Wood [41], 
cross-sectional 
Newcastle, 
Australia 
21 people with CF (M = 61.9; 14.8 ± 1.1 y); 57% 
were F508del homozygous; 38% were F508del 
heterozygous; 5% were non F508del.  Mean ± 
SEM FEV1 was 85.3 ± 6.2% predicted and FVC 
was 90.1 ± 4.7% predicted. 91% were PI; 71% 
were receiving aerosol β2-agonists; 33% were 
receiving inhaled corticosteroids; 14% were 
receiving cromoglycate; 24% were receiving 
ipratropium; 19% were receiving DNase; 19% 
were receiving antibiotics. None received vitamin 
supplementation in the previous 4 wk.  
21 HCP (M = 61.9; 14.2 ± 1.1 y) 
matched for age and sex. 
Erythrocyte SOD. 
Plasma 8-iso-PGF2α, 
β-carotene, GPx, 
selenium, zinc, 
copper, vitamins A, C 
and E. 
Madarasi [61], 
cross-sectional 
Budapest, 
Hungary 
21 people with CF (M = 57.1; mean (range), 8.7 
(6-12) y). None had liver manifestations; 100.0% 
received pancreatic enzyme replacement and 
multivitamin supplements. 
24 HCP (M = 45.8; mean (range), 8.3 
(6-12) y) matched for age. HCP were 
formally hospitalised children with 
minor ailments who were attending 
clinic for follow-up blood testing.  
Erythrocyte CAT and 
SOD. Serum α-
tocopherol, ascorbic 
acid, MDA, TAC, 
uric acid and vitamin 
A. Whole blood GPx. 
Lands [73], 
cross-sectional 
Montreal, 
Canada 
24 people with CF (M = 62.5; 11.4 ± 3.4 y), who 
were not hospitalised for an acute respiratory 
exacerbation. Mean ± SD FEV1 was 77.6 ± 17.4% 
predicted and RV/TLV was 31.1 ± 10.3%. 
17 HCP (M = 58.8; 23.8 ± 3.9 y) who 
were recruited as part of a study 
investigating oxidative stress and 
exercise. 
Plasma trolox 
equivalent 
antioxidant capacity 
(TEAC). 
Percival [70], 
cross-sectional 
Florida, USA 7 people with CF (M = 100.0; 24.5 ± 3.5 y, range 
19-32 y). Mean ± SD FEV1 was 55.0 ± 28.8% 
(range 25-99%) and FVC was 75.8 ± 20.2% (51-
105%) predicted. 85.7% were PI and receiving 
pancreatic enzyme replacement supplements. All 
were receiving multivitamin supplements. 
 
6 HCP (M = 100.0; 24.5 ± 5.5 y, range 
20-30 y) who were matched for age.  
Plasma, 
polymorphonuclear 
cell and mononuclear 
cell copper. 
Polymorphonuclear 
cell and mononuclear 
cell Copper-Zinc 
SOD. Plasma 
ceruloplasmin. 
Tauber [143], 
cross-sectional 
Vienna, 
Austria 
28 people with CF (M = 51.1; 10.8 ± 6.5 y; this 
includes those with an acute respiratory 
exacerbation (n = 17)) who did not have an acute 
respiratory exacerbation; 4.4% of all (including 
those with an acute respiratory exacerbation) had 
chronic P. aeruginosa infections.  
175 children with bronchial asthma 
(BA) (M = 55.4; 9.8 ± 3.8 y); 87 HCP 
(M = 29.9; 10.2 ± 4.5 y); 23 non-
asthmatic children with bacterial lower 
respiratory tract infection (LRTI) (M = 
39.1; 8.6 ± 2.5 y). 
Serum  
myeloperoxidase  
(MPO). 
Collins [75], New South 10 people with CF (sex NR; mean (range), 17.4 9 HCP (sex NR; mean (range), 29.8 Plasma 8-iso-PGF2α. 
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cross-sectional Wales, 
Australia 
(5.8-37.8) y; this includes those with an acute 
respiratory exacerbation (n = 12)), who are not 
undergoing treatment for an acute respiratory 
exacerbation.  
(22.8-46.1) y). 
Eichler [144], 
cross-sectional 
Vienna, 
Austria 
23 people with CF (M = 57.1; median (range), 
14.5 (8-17) y; this includes those with an acute 
respiratory exacerbation (n = 19)). In those who 
were clinically-stable, median (IQR) FEV1 was 
81.2% (72.4-98.4) and FVC was 87.8% (79.6-
102.3%) predicted. 
25 HCP (M = 56.0; median (range), 
13.4 (3-16) y). 
Serum lactoferrin and 
MPO. 
Dominguez [64], 
cross-sectional 
Barcelona, 
Spain 
101 people with CF (M = 54.5%; 11.5 ± 6.9 y). 43-95 HCP (varies between 
biomarkers) of a similar age to the CF 
group (age and sex NR). 
Erythrocyte SOD. 
Plasma α-tocopherol, 
glutathione reductase 
(GR), 
hydroperoxides, 
MDA and protein 
carbonyls. 
Koller [145], 
cross-sectional 
Vienna, 
Austria 
23 people with CF (M = 57.1; median (range), 
14.5 (8-17) y; this includes those with an acute 
respiratory exacerbation (n = 19)), without an 
acute respiratory exacerbation. Median (quartile 
1-3) FEV1 was 81.2 (72.4-98.4)% and FVC was 
87.8 (79.6-102.3)%. 
 
25 HCP (M = 56.0; median (range), 
13.4 (3-16) y). 
Serum eosinophil 
peroxidase. 
Hung [89], 
cross-sectional 
Edinburgh, 
UK 
63 people with CF (M = 49.2; mean (range) 7.9 
(0.5-16) y). All participants were receiving 
pancreatic enzyme replacement and multivitamin 
supplements; all participants were receiving 
flucloxacillin, inhaled steroids and/or inhaled 
steroid and bronchodilators. 
59 HCP (M = 62.7; mean (range), 7.2 
(1-16) y). 96.6% were screened for CF 
and fragile X syndrome but had normal 
genotypes; 1.7% had bronchiolitis; 
1.7% had an inguinal hernia. 
Serum GSTα1. 
Kearns [46], 
cross-sectional 
Arkansas, 
USA 
15 people with CF (M = 46.7%; 13.1 ± 2.7 y, 
range 8.7-19.3 y); 7/15 had genotype analysis; 
100% were F508del homozygous; 13.3% were 
receiving pancreatic enzyme replacement and 
multivitamin supplements.  
15 HCP (M = 46.7%; 14.5 ± 3.1 y, 
range 8.9-18.9 y). 
Serum albumin and  
(γ-glutamyl 
transpeptidase) GGT. 
Koller [146], 
cross-sectional 
Vienna, 
Austria 
59 people with CF (M = 45.9%; 11.0 ± 7.7 y; this 
includes those with an acute respiratory 
85 HCP (M = NR; 10.8 ± 5.7 y). Serum MPO. 
 Table 1. Characteristics of included studies.  
61 
 
First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
exacerbation (n = 39)) without an acute 
respiratory exacerbation. 
Winklehofer-Roob 
[56],   
pre-β-alanine 
intervention 
Zurich, 
Switzerland 
Up to 32 people with CF (M = 48.6%; 10.8 ± 7.6 
y); 100.0 were PI and receiving pancreatic 
enzyme replacement and multivitamin 
supplements. 
Up to 40 HCP (M = 35.7%; 31.5 ± 8.0 
y). 
LDL α-tocopherol 
and β-carotene. 
Plasma α-tocopherol, 
β-carotene and MDA. 
Mocchegiani [47], 
cross-sectional 
Ancona, Italy 15 people with CF (M = 46.7%; mean (range), 6.7 
(2-13) y); 90% were colonized with P. 
aeruginosa. All were receiving pancreatic enzyme 
replacement and vitamin supplementation. No 
individuals with signs of diabetes or heart failure 
were included. All were receiving antibiotics and 
bronchodilators. 
15 HCP (M = 60.0%; mean (range), 
NR (2-13) y) who were admitted to 
hospital for minor surgery. 
Serum albumin. 
Plasma Zinc. 
Koller [147], 
cross-sectional 
Vienna, 
Austria 
42 people with CF (M = 47.6%; mean (range), 
14.5 (0.8-28) y). Mean ± SD FEV1 was 67.8 ± 
32.4% predicted (range 17.1-125.5% predicted), 
MEF50 was 52.0 (42.5)% predicted (range 4.4-
130.2% predicted). 73.3% were colonized with P. 
aeruginosa. 
30 HCP (M = 53.3%; mean (range), 
13.4 (4-32) y). 
Serum MPO. 
Mangione [51], 
cross-sectional 
Pennsylvania, 
USA 
32 people with CF (age and sex NR). 8 HCP who were healthy, active, non-
smokers and age-matched to their CF-
counterparts.  
Erythrocyte GSH. 
Vaisman [62], 
cross-sectional 
Rehovot, 
Israel 
11 people with CF (mean (range), NR (4-14) y). 
“Most” were colonized with P. aeruginosa. All 
were receiving vitamin A and E supplements (100 
IU) and multivitamin preparations. 
 
 
10 age-matched HCP (age and sex 
NR). Not receiving any vitamin 
supplementation.  
Plasma tocopherol 
vitamin A. Blood 
neutrophil 
tocopherol. 
James [38], 
cross-sectional 
Cardiff, UK 22 people with CF (M = 45.5%; median (range), 
8.3 (1.6-16.5) y). 
9 HCP (M = 22.2%; median (range), 
10.9 (4.7-16.4) y). 
Plasma and 
erythrocyte α-
tocopherol. Serum 
selenium. 
Stead [50], 
cross-sectional 
London, UK 31 people with CF (24.5 y (range, 17-52 y)); 
93.5% receiving pancreatic enzyme replacement 
and no evidence of liver disease. FEV1 was 41.5 ± 
11.4% predicted.  96.8% taking vitamin D 
supplements (daily intake range: 0.6-54.3 µg [24-
28 HCP (M = NR; age = NR). Serum 25(OH)D,  
and 1,25(OH)2D. 
Plasma albumin. 
 Table 1. Characteristics of included studies.  
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
Data is expressed as mean ± standard deviation (SD) unless otherwise stated. 
2,172 IU)]. 
Reiter [65], 
cross-sectional 
Massachusetts 
and Arizona, 
USA 
20 people with CF (M = 50.0%; range, 12-25 y); 
50% in Massachusetts and 50% in Arizona. All 
were receiving pancreatic enzyme replacement, 
vitamin supplementation and intermittent 
antibiotic therapy.   
8 HCP (M = 40.0%; 18.6 ± 8.1 y). Serum carotene, 
albumin and 
1,25(OH)2D. 
Hahn [48], 
cross-sectional 
St. Louis, 
USA 
21 people with CF (M = 57.1%; mean (range), 
20.9 (12-36) y). All were PI. All were receiving 
pancreatic enzyme replacement (given as 
Cotazyme) and multivitamin supplements 
(containing 400 units of vitamin D/tablet).  One 
patient had diabetes and was receiving oral 
hypoglycaemic agents.  
21 age- and sex-matched HCP (M = 
57.1%; mean (range), 20.3 (12-34) y). 
Serum 25(OH)D, 
albumin and 
carotene. 
Jacob [49], 
cross-sectional 
Chicago, USA 18 people with CF (range, 6-17 y). All were 
receiving daily multivitamin supplements (Poly-
vi-sol) containing 2,500 IU of water miscible 
vitamin A per tablet.  
40 adolescent HCP (range, 11-17 y). Plasma vitamin A, 
zinc and albumin.   
Hubbard [55], 
cross-sectional 
Tennessee, 
USA 
16 people with CF (M = 43.8%; range, 13-47 y); 
68.8% were PI. Those with PI were receiving 
pancreatic enzyme replacement and multivitamin 
supplements.  
8 HCP (M = 50.0%; range, 19-32 y). Serum vitamin A and 
carotene. Plasma 
vitamin E. 
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Table 2. Summary of the quality ratings for the eligible studies using the Newcastle-Ottawa Quality 
Assessment Scale for case-control studies.   
First author [reference] Selection Comparability Exposure Total points Rating1 
AbdulWahab [69] 2 1 3 6 High 
Ambroszkiewicz [60] 3 2 2 7 High 
Antus [74] 3 0 1 4 Moderate 
Aris [68] 2 1 3 6 High 
Back [42] 1 1 2 4 Moderate 
Bernardi [39] 2 1 2 5 Moderate 
Best [71] 1 1 3 5 Moderate 
Cobanoglu [66] 2 2 3 7 High 
Collins [75] 3 0 3 6 High 
Dominguez [64] 1 1 1 3 Moderate 
Durieu [43] 0 0 2 2 Low 
Eichler [144] 2 0 1 3 Moderate 
Hahn [48] 2 2 3 7 High 
Hubbard [55] 2 0 1 3 Moderate 
Hung [89] 3 0 1 4 Moderate 
Jacob [49] 2 0 2 4 Moderate 
James [38] 0 0 2 2 Low 
Kearns [46] 1 1 2 4 Moderate 
Koller [145] 1 0 2 3 Moderate 
Koller [146] 0 0 2 2 Low 
Koller [147] 1 0 2 3 Moderate 
Konstantinidis [139] 1 1 3 5 Moderate 
Lagrange-Puget [7] 2 0 2 4 Moderate 
Lands [73] 1 0 2 3 Moderate 
Lee [45] 2 0 1 3 Moderate 
Madarasi [61] 1 1 2 4 Moderate 
Mangione [51] 0 1 3 4 Moderate 
McGrath [54] 3 2 3 8 High 
Mocchegiani [47] 1 1 3 5 Moderate 
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Table 2. Continued.      
First author [reference] Selection Comparability Exposure Total points Rating1 
Nicolaidou [44] 2 0 3 5 Moderate 
Olveira [58] 1 2 3 6 High 
Olveira [52] 0 1 3 4 Moderate 
Oudshoorn [63] 0 1 3 4 Moderate 
Percival [70] 3 1 3 7 High 
Reiter [65] 3 2 3 8 High 
Rovner [67] 3 0 3 6 High 
Sadowska-Bartosz [53] 1 0 3 4 Moderate 
Sadowska-Woda [72] 0 1 3 4 Moderate 
Schupp [57] 2 2 3 7 High 
Sidlova [88] 2 0 3 5 Moderate 
Stead [50] 2 1 2 5 Moderate 
Tauber [143] 0 1 2 3 Moderate 
Tirouvanziam [40] 1 0 3 4 Moderate 
Turowski [140] 2 0 3 5 Moderate 
Vaisman [62] 0 1 3 4 Moderate 
Van Biervliet [142] 2 0 3 5 Moderate 
Winklhofer-Roob [56] 2 0 2 4 Moderate 
Wood [41] 4 2 3 9 High 
Yadav [59] 2 1 3 6 High 
1
 Studies scoring 0-2 were considered low quality, studies scoring 3-5 were considered moderate quality and studies 
scoring 6-8 points were considered high quality. 
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Table 3. Statistically significant correlation coefficients for biomarkers of antioxidant status, oxidative 
damage and clinical outcomes. 
First author 
[reference] Biomarker Sample Clinical outcome r 
Vitamins 
   
Lagrange-Puget [7] Vitamin A P/S BMI FEV1 
+NR 
+NR 
Madarasi [61] Vitamin A P/S Shwachman-Kulzycki score +0.75 
Lagrange-Puget [7] β-carotene P/S BMI FEV1 
+NR 
+NR 
Wood [41] β-carotene P/S 
Monocyte count 
Neutrophil count 
White cell count 
-0.311 
-0.461 
-0.421 
Lagrange-Puget [7] Lutein P/S BMI +NR 
Schupp [57] Lutein P/S Macular pigment optical density +0.76 
Lagrange-Puget [7] Lycopene P/S BMI FEV1 
+NR 
+NR 
Lagrange-Puget [7] Zeaxanthin P/S FEV1 +NR 
Schupp [57] Zeaxanthin P/S Macular pigment optical density +0.80 
Madarasi [61] Vitamin C P/S Shwachman-Kulzycki score +0.49 
Back [42] Vitamin C P/S Age FEV1 
-0.77 
+0.50 
Aris [68] Vitamin D P/S 
Serum intact parathyroid hormone 
Serum osteocalcin 
Urinary free deoxypyridinoline 
-NR 
+NR 
-NR 
Hahn [48] Vitamin D P/S Serum calcium Diaphyseal bone mass 
+0.54 
+0.42 
Aris [68] 1,25(OH)2D P/S 
Serum intact parathyroid hormone 
Serum osteocalcin 
Urinary free deoxypyridinoline 
-NR 
+NR 
-NR 
Back [42] Vitamin E P/S Age FEV1 
-0.47 
+0.46 
Lagrange-Puget [7] Vitamin E P/S FEV1 +NR 
Oudshoorn [63] Vitamin E P/S Coenzyme Q10 +0.40 
Wood [41] Vitamin E P/S Monocyte count Neutrophil count 
-0.341 
-0.341 
Trace elements 
    
AbdulWahab [69] Zinc P/S 
BMI 
FEV1 
FEV1/FVC 
FVC 
+NR 
+NR 
+NR 
+NR 
Jacob [49] Zinc P/S 
Age 
Retinol binding protein 
Vitamin A 
-0.63 
+0.64 
+0.51 
Mocchegiani [47] Zinc P/S 
Interleukin-2 
Weight/age (percentile) 
Weight/height deficits (%) 
+0.791 
+0.861 
+0.941 
 
 
 
 
 
    
  
 
66 
 
Table 3. Continued.    
First author 
[reference] Biomarker Sample Clinical outcome r 
Thiols 
   
Mangione [51] Glutathione Erythrocyte FEV1 FVC 
-0.30 
+0.35 
Other antioxidants  
   
Lands [73] TEAC P/S 
BMI 
FEV1 
Uric acid 
Height 
Weight 
RV/TLC 
+0.472 
+0.432 
+0.492 
+0.392 
+0.502 
-0.422 
Lipid peroxidation  
   
Wood [41] 8-iso-PGF2α P/S 
P/S β-carotene 
P/S vitamin C 
P/S vitamin E 
Monocyte count 
Neutrophil count 
White cell count 
-0.421 
-0.431 
-0.371 
+0.371 
+0.311 
+0.311 
Lagrange-Puget [7] MDA P/S Age +NR 
Lagrange-Puget [7] TBARS P/S Age BMI 
+NR 
-NR 
1
 Denotes that both case and control participants were included in the correlation analysis; 2 Denotes that both 1223 
non-hospitalized and hospitalized participants were included in the correlation analysis. +, statistically 1224 
significant positive correlation (p ≤ 0.05); -, denotes statistically significant negative correlation (p ≤ 0.05); 8-1225 
iso-PGF2α, F2-isoprostane 8-iso-prostaglandin F2α; BMI, body mass index; FEV1, forced expiratory volume in 1 1226 
s; MDA, malondialdehyde; NR, correlation coefficient not reported, but there was a statically significant 1227 
correlation (p ≤ 0.05); P/S, plasma or serum; PICP, serum carboxy-terminal propeptide of type I procollagen; 1228 
PINP, serum amino-terminal propeptide of type I procollagen; r, correlation coefficient; RV/TLC, residual 1229 
volume/total lung capacity; TEAC, trolox equivalent antioxidant capacity; TBARS, Thiobarbituric acid reactive 1230 
substances. 1231 
 1232 
 1233 
 1234 
 1235 
 1236 
 1237 
 1238 
 1239 
 1240 
 1241 
 1242 
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HIGHLIGHTS 
• Blood biomarkers of oxidative stress were elevated in stable CF vs non-CF controls 
• Lipid peroxidation was positively correlated with age and immune cell count in CF 
•  Antioxidants vitamins A & E, β-carotene, lutein and albumin were lower in stable CF 
• Antioxidants were positively correlated with body mass index and lung function in CF 
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